Tokyo Tape
Sign in
← Carna Biosciences

Annual report

4572.TEDINET S100T2Q7
Period2023-01-01 → 2023-12-31
Filed2024-03-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 137
MetricValuePeriodScopeSource row
Revenue¥1.6bn2023-01-01 → 2023-12-31Cons.Net sales
Revenue¥1.4bn2022-01-01 → 2022-12-31Cons.Net sales
Revenue¥2.0bn2021-01-01 → 2021-12-31dCons.Net sales (5-year summary)
Revenue¥1.1bn2020-01-01 → 2020-12-31dCons.Net sales (5-year summary)
Revenue¥3.2bn2019-01-01 → 2019-12-31dCons.Net sales (5-year summary)
Operating income−¥1.1bn2023-01-01 → 2023-12-31Cons.Operating income
Operating income−¥1.3bn2022-01-01 → 2022-12-31Cons.Operating income
Ordinary income−¥1.1bn2023-01-01 → 2023-12-31Cons.Ordinary income
Ordinary income−¥1.3bn2022-01-01 → 2022-12-31Cons.Ordinary income
Ordinary income−¥523m2021-01-01 → 2021-12-31dCons.Ordinary income loss (5-year summary)
Ordinary income−¥1.1bn2020-01-01 → 2020-12-31dCons.Ordinary income loss (5-year summary)
Ordinary income¥957m2019-01-01 → 2019-12-31dCons.Ordinary income loss (5-year summary)
Profit before tax−¥1.1bn2023-01-01 → 2023-12-31Cons.Income before income taxes
Profit before tax−¥1.3bn2022-01-01 → 2022-12-31Cons.Income before income taxes
Net income (owners)−¥1.2bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.3bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥534m2021-01-01 → 2021-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.1bn2020-01-01 → 2020-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥828m2019-01-01 → 2019-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income−¥1.2bn2023-01-01 → 2023-12-31Cons.Profit loss
Net income−¥1.3bn2022-01-01 → 2022-12-31Cons.Profit loss
Total assets¥4.3bnat 2023-12-31Cons.Assets
Total assets¥4.3bnat 2022-12-31Cons.Assets
Total assets¥5.4bnat 2021-12-31dCons.Total assets (5-year summary)
Total assets¥4.8bnat 2020-12-31dCons.Total assets (5-year summary)
Total assets¥5.4bnat 2019-12-31dCons.Total assets (5-year summary)
Total liabilities¥472mat 2023-12-31Cons.Liabilities
Total liabilities¥625mat 2022-12-31Cons.Liabilities
Net assets / equity¥3.9bnat 2023-12-31Cons.Net assets
Net assets / equity¥3.6bnat 2022-12-31Cons.Net assets
Net assets / equity¥4.3bnat 2021-12-31dCons.Net assets
Net assets / equity¥3.8bnat 2020-12-31dCons.Net assets (5-year summary)
Net assets / equity¥3.9bnat 2019-12-31dCons.Net assets (5-year summary)
Cash and deposits¥2.9bnat 2023-12-31Cons.Cash and deposits
Cash and deposits¥3.4bnat 2022-12-31Cons.Cash and deposits
Cash & equivalents¥2.9bnat 2023-12-31Cons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥3.8bnat 2021-12-31dCons.Cash and cash equivalents
Cash & equivalents¥4.3bnat 2020-12-31dCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥4.9bnat 2019-12-31dCons.Cash and cash equivalents (5-year summary)
Operating cash flow−¥1.7bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥708m2022-01-01 → 2022-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.5bn2021-01-01 → 2021-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.3bn2020-01-01 → 2020-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.5bn2019-01-01 → 2019-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥11m2023-01-01 → 2023-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥126m2022-01-01 → 2022-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥42m2021-01-01 → 2021-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥70m2020-01-01 → 2020-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥41m2019-01-01 → 2019-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.2bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in financing activities
Financing cash flow¥367m2022-01-01 → 2022-12-31Cons.Net cash provided by used in financing activities
Financing cash flow¥1.1bn2021-01-01 → 2021-12-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥724m2020-01-01 → 2020-12-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.1bn2019-01-01 → 2019-12-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-68.622023-01-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-99.12022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-42.12021-01-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-90.332020-01-01 → 2020-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥76.052019-01-01 → 2019-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥74.512019-01-01 → 2019-12-31dCons.Diluted earnings per share (5-year summary)
Net assets per share¥226.16at 2023-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥255.04at 2022-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥323.54at 2021-12-31dCons.Net assets per share (5-year summary)
Net assets per share¥308.05at 2020-12-31dCons.Net assets per share (5-year summary)
Net assets per share¥329.86at 2019-12-31dCons.Net assets per share (5-year summary)
Equity ratio89.1%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio85.0%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio79.3%at 2021-12-31dCons.Equity to asset ratio (5-year summary)
Equity ratio79.0%at 2020-12-31dCons.Equity to asset ratio (5-year summary)
Equity ratio71.5%at 2019-12-31dCons.Equity to asset ratio (5-year summary)
ROE35.1%2019-01-01 → 2019-12-31dCons.Rate of return on equity (5-year summary)
Employees67at 2023-12-31Cons.Number of employees
Employees65at 2022-12-31Cons.Number of employees
Employees64at 2021-12-31dCons.Number of employees
Employees64at 2020-12-31dCons.Number of employees
Employees63at 2019-12-31dCons.Number of employees
Revenue¥1.5bn2023-01-01 → 2023-12-31StandaloneNet sales
Revenue¥1.2bn2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥1.9bn2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Revenue¥1.0bn2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥3.1bn2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.2bn2023-01-01 → 2023-12-31StandaloneOperating income
Operating income−¥1.3bn2022-01-01 → 2022-12-31StandaloneOperating income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income−¥1.4bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income−¥549m2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.1bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥874m2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.2bn2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Profit before tax−¥1.4bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Net income−¥1.2bn2023-01-01 → 2023-12-31StandaloneProfit loss
Net income−¥1.4bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income−¥556m2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income−¥1.1bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income¥746m2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Total assets¥4.1bnat 2023-12-31StandaloneAssets
Total assets¥4.0bnat 2022-12-31StandaloneAssets
Total assets¥5.3bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥4.7bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥5.3bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥462mat 2023-12-31StandaloneLiabilities
Total liabilities¥607mat 2022-12-31StandaloneLiabilities
Net assets / equity¥3.6bnat 2023-12-31StandaloneNet assets
Net assets / equity¥3.4bnat 2022-12-31StandaloneNet assets
Net assets / equity¥4.2bnat 2021-12-31dStandaloneNet assets
Net assets / equity¥3.7bnat 2020-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥3.8bnat 2019-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.6bnat 2023-12-31StandaloneCash and deposits
Cash and deposits¥3.1bnat 2022-12-31StandaloneCash and deposits
EPS (basic)¥-70.532023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-103.22022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-43.832021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-91.842020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥68.472019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥67.082019-01-01 → 2019-12-31dStandaloneDiluted earnings per share (5-year summary)
Net assets per share¥211.43at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥240.82at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥314.45at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥301.39at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥323.68at 2019-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio88.7%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio84.6%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio78.9%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio78.7%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio71.1%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE32.0%2019-01-01 → 2019-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued17,151,900at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued14,218,300at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued13,313,400at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued12,407,100at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued11,654,500at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees64at 2023-12-31StandaloneNumber of employees
Employees62at 2022-12-31StandaloneNumber of employees
Employees61at 2021-12-31dStandaloneNumber of employees
Employees61at 2020-12-31dStandaloneNumber of employees
Employees60at 2019-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 42
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment assetsat 2023-12-31¥2.7bn
Drug Discovery Businessreportable segmentcapex2023-01-01 → 2023-12-31¥5m
Drug Discovery Businessreportable segmentdepreciation2023-01-01 → 2023-12-31¥12m
Drug Discovery Businessreportable segmentemployeesat 2023-12-3134 pure
Drug Discovery Businessreportable segmentrevenue2023-01-01 → 2023-12-31¥708m
Drug Discovery Businessreportable segmentrevenue external2023-01-01 → 2023-12-31¥708m
Drug Discovery Businessreportable segmentsegment assetsat 2023-12-31¥1.0bn
Drug Discovery Businessreportable segmentsegment profit2023-01-01 → 2023-12-31−¥1.3bn
Drug Discovery Support Businessreportable segmentcapex2023-01-01 → 2023-12-31¥39m
Drug Discovery Support Businessreportable segmentdepreciation2023-01-01 → 2023-12-31¥23m
Drug Discovery Support Businessreportable segmentemployeesat 2023-12-3124 pure
Drug Discovery Support Businessreportable segmentrevenue2023-01-01 → 2023-12-31¥918m
Drug Discovery Support Businessreportable segmentrevenue external2023-01-01 → 2023-12-31¥918m
Drug Discovery Support Businessreportable segmentsegment assetsat 2023-12-31¥633m
Drug Discovery Support Businessreportable segmentsegment profit2023-01-01 → 2023-12-31¥226m
—segment totalcapex2023-01-01 → 2023-12-31¥45m
—segment totaldepreciation2023-01-01 → 2023-12-31¥36m
—segment totalrevenue2023-01-01 → 2023-12-31¥1.6bn
—segment totalrevenue external2023-01-01 → 2023-12-31¥1.6bn
—segment totalsegment assetsat 2023-12-31¥1.7bn
—segment totalsegment profit2023-01-01 → 2023-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment assetsat 2022-12-31¥3.2bn
Drug Discovery Businessreportable segmentcapex2022-01-01 → 2022-12-31¥68m
Drug Discovery Businessreportable segmentdepreciation2022-01-01 → 2022-12-31¥13m
Drug Discovery Businessreportable segmentrevenue2022-01-01 → 2022-12-31¥286m
Drug Discovery Businessreportable segmentrevenue external2022-01-01 → 2022-12-31¥286m
Drug Discovery Businessreportable segmentsegment assetsat 2022-12-31¥373m
Drug Discovery Businessreportable segmentsegment profit2022-01-01 → 2022-12-31−¥1.7bn
Drug Discovery Support Businessreportable segmentcapex2022-01-01 → 2022-12-31¥58m
Drug Discovery Support Businessreportable segmentdepreciation2022-01-01 → 2022-12-31¥21m
Drug Discovery Support Businessreportable segmentrevenue2022-01-01 → 2022-12-31¥1.1bn
Drug Discovery Support Businessreportable segmentrevenue external2022-01-01 → 2022-12-31¥1.1bn
Drug Discovery Support Businessreportable segmentsegment assetsat 2022-12-31¥685m
Drug Discovery Support Businessreportable segmentsegment profit2022-01-01 → 2022-12-31¥453m
—segment totalcapex2022-01-01 → 2022-12-31¥126m
—segment totaldepreciation2022-01-01 → 2022-12-31¥34m
—segment totalrevenue2022-01-01 → 2022-12-31¥1.4bn
—segment totalrevenue external2022-01-01 → 2022-12-31¥1.4bn
—segment totalsegment assetsat 2022-12-31¥1.1bn
—segment totalsegment profit2022-01-01 → 2022-12-31−¥1.3bn
Drug Discovery Businessreportable segmentemployeesat 2023-12-3133 pure
Drug Discovery Support Businessreportable segmentemployeesat 2023-12-3122 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,305
ItemContextValueUnit
Interest income noiPrior1YearDuration147000JPY
Interest income noiCurrentYearDuration170000JPY
Dividends income noiPrior1YearDuration411000JPY
Dividends income noiCurrentYearDuration426000JPY
Insurance income noiPrior1YearDuration1957000JPY
Insurance income noiCurrentYearDuration－JPY
Subsidy income noi bountyPrior1YearDuration1000000JPY
Subsidy income noi bountyCurrentYearDuration－JPY
Foreign exchange gains noiPrior1YearDuration830000JPY
Foreign exchange gains noiCurrentYearDuration－JPY
Other noiPrior1YearDuration1243000JPY
Other noiCurrentYearDuration159000JPY
Non operating incomePrior1YearDuration5590000JPY
Non operating incomeCurrentYearDuration756000JPY
Interest expenses noePrior1YearDuration5310000JPY
Interest expenses noeCurrentYearDuration3451000JPY
Guarantee commission noePrior1YearDuration977000JPY
Guarantee commission noeCurrentYearDuration676000JPY
Stock issuance cost noePrior1YearDuration2682000JPY
Stock issuance cost noeCurrentYearDuration5219000JPY
Share acquisition rights issuance costs noePrior1YearDuration5501000JPY
Share acquisition rights issuance costs noeCurrentYearDuration－JPY
Foreign exchange losses noePrior1YearDuration－JPY
Foreign exchange losses noeCurrentYearDuration714000JPY
Other noePrior1YearDuration49000JPY
Other noeCurrentYearDuration0JPY
Non operating expensesPrior1YearDuration14522000JPY
Non operating expensesCurrentYearDuration10061000JPY
Ordinary incomePrior1YearDuration-1278820000JPY
Ordinary incomeCurrentYearDuration-1126283000JPY
Impairment loss elPrior1YearDuration44578000JPY
Impairment loss elCurrentYearDuration4562000JPY
Extraordinary lossPrior1YearDuration44578000JPY
Extraordinary lossCurrentYearDuration4562000JPY
Income before income taxesPrior1YearDuration-1323399000JPY
Income before income taxesCurrentYearDuration-1130846000JPY
Income taxes currentPrior1YearDuration26262000JPY
Income taxes currentCurrentYearDuration22161000JPY
Income taxes deferredPrior1YearDuration-122000JPY
Income taxes deferredCurrentYearDuration-113000JPY
Income taxesPrior1YearDuration26140000JPY
Income taxesCurrentYearDuration22048000JPY
Profit lossPrior1YearDuration-1349539000JPY
Profit lossCurrentYearDuration-1152895000JPY
Profit loss attributable to owners of parentPrior1YearDuration-1349539000JPY
Profit loss attributable to owners of parentCurrentYearDuration-1152895000JPY
Profit lossPrior1YearDuration-1349539000JPY
Profit lossCurrentYearDuration-1152895000JPY
Valuation difference on available for sale securities net of tax ociPrior1YearDuration-1742000JPY
Valuation difference on available for sale securities net of tax ociCurrentYearDuration-349000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-12-31pass
balance sheet identitynon_consolidated 2022-12-31pass
balance sheet identitynon_consolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-12-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass